Synthesis, preclinical evaluation and antidepressant activity of 5-substituted phenyl-3-(thiophen-2-yl)-4, 5- dihydro-1H-pyrazole-1-carbothioamides

EXCLI Journal

Volumn 13, Issue , 2014, Pages 437-445

  Mathew, Bijo ^a   Suresh, Jerad ^b   Anbazhagan, S ^c  

^a Grace College of Pharmacy   (India)

^b MADRAS MEDICAL COLLEGE   (India)

^c Surya School of Pharmacy   (India)

Author keywords

2 acetyl thiophene; Force swimming test; Neurotoxicity; Pyrazoline; Total polar surface area

Indexed keywords

3 PHENYL 1 (THIOPHEN 2 YL) PROP 2 EN 1 ONE DERIVATIVE; 5 (2 HYDROXYPHENYL) 3 (THIOPHEN 2 YL) 4, 5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; 5 (3 NITROPHENYL) 3 (THIOPHEN 2 YL) 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; 5 (4 CHLOROPHENYL) 3 (THIOPHEN 2 YL) 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; 5 (4 HYDROXYPHENYL) 3 (THIOPHEN 2 YL) 4, 5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; 5 (4 HYDROXYPHENYL) 3 (THIOPHEN 2 YL) 4,5 DIHYDRO 1H PYRAZOLE 1 CARBOTHIOAMIDE; 5 (4 METHOXYPHENYL) 3 (THIOPHEN 2 YL) 4, 5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; 5 PHENYL 3 (THIOPHEN 2 YL) 4, 5 DIHYDRO 1H PYRAZOLE 1 CARBOTHIOAMIDE DERIVATIVE; 5 [4 (DIMETHYLAMINO) PHENYL] 3 (THIOPHEN 2 YL) 4, 5 DIHYDRO 1H PYRAZOLE 1 CARBOXAMIDE; ANTIDEPRESSANT AGENT; IMIPRAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CARBON NUCLEAR MAGNETIC RESONANCE; CYCLIZATION; DRUG ABSORPTION; DRUG STRUCTURE; DRUG SYNTHESIS; FORCED SWIM TEST; HUMAN; IMMOBILITY; IN VIVO STUDY; MOTOR COORDINATION; MOUSE; NEUROTOXICITY; NONHUMAN; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TAIL SUSPENSION TEST; TOXICITY TESTING;

EID: 84899754973     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Aboul-Enein MN, El-Azzouny AA, Attia MI, Maklad YA, Amin KM, Abdel-Rehim M et al. Design and synthesis of novel stiripentol analogues as potential anticonvulsants. Eur J Med Chem 2012; 47; 360-9.
2. Chimenti F, Bolasco A, Manna F, Secci D, Chimenti P, Befani O et al. Synthesis and selective inhibitory activity of 1-Acetyl-3, 5-diphenyl-4, 5-dihydro-(1H)-pyrazole derivatives against Monoamine oxidase. J Med Chem 2004; 47: 2071-4.
3. Gok S, Demet MM, Ozdemir A, Turan-Zitouni G. Evaluation of antidepressant-like effect of 2-pyrazoline derivatives. Med Chem Res 2010; 19: 94-101.
4. Kaplanci{dotless}kli{dotless} ZA, Özdemir A, Turan-Zitouni G, Alti{dotless}ntop MD, Can OD. New pyrazoline derivatives and their antidepressant activity. Eur J Med Chem 2010; 45: 4383-7.
5. Karuppasamy M, Mahapatra S, Yabanoglu S, Ucar G, Sinha BN, Basu A et al. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg Med Chem 2010; 18: 1875-81.
6. Kumar A, Jain S, Parle M, Jain N, Kumar P. Aryl-1-phenyl-1H-pyrazole derivatives as new multitarget directed ligands for the treatment of alzheimer's disease, with acetylcholinesterase and monoamine oxidase inhibitory properties. EXCLI J 2013; 12: 1030-42.
7. Mathew B, Suresh J, Anbazhagan S, Mathew GE. Pyrazoline: A promising scaffold for the inhibition of Monoamine oxidase. Cent Nerv Syst Agents Med Chem 2013a; 13: 195-206.
8. Mathew B, Suresh J, Anbazhagan S. Antitumor activity of 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-substituted phenylprop-2-en-1-ylidene] pyrimidine-2, 4, 6 (1H, 3H, 5H) triones against Dalton's Ascitic Lymphoma in mice. Med Chem Res 2013b; 22: 3911-7.
9. Nayak BV, Ciftci-Yabanoglu S, Singh S, Jagrat M, Sinha BN, Ucar G et al. Monoamine oxidase inhibitory activity of 3, 5-biaryl-4, 5-dihydro-1H-pyrazole-1-carboxylate derivatives. Eur J Med Chem 2013; 69: 762-7.
10. Ozdemir Z, Kandilci HB, Gumusel B, Calis U, Bilgin AA. Synthesis and studies on anti-depressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. Eur J Med Chem 2007; 42: 373-9.
11. Palaska E, Aytemir M, Uzbay IT, Erol D. Synthesis and antidepressant activities of some 3, 5-diphenyl-2-pyrazolines. Eur J Med Chem 2001; 36: 539-43.
12. Parmar SS, Pandey BR, Dwivedi C, Harbison RD. Anticonvulsant activity and monoamine oxidase inhibitory properties of1, 3, 5-trisubstituted pyrazolines. J Pharm Sci 1974; 63: 1152-5.
13. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-36.
14. Prasad YR, Rao AL, Prasoona L, Murali K, Kumar PR. Synthesis and antidepressant activity of some 1, 3, 5-triphenyl-2-pyrazolines and 3-(2-hydroxy naphthalen-1-yl)-1, 5-diphenyl-2-pyrazolines. Bioorg Med Chem Lett 2005; 15: 5030-4.
15. Salgi{dotless}n-Goksen U, Yabanoglu-Ciftci S, Ercan A, Yelekci K, Ucar G, Gokhan-Kelekci N. Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives. J Neural Transm 2013; 120: 863-73.
16. Sander T, Freyss J, Korff MV, Reich JR, Rufener C. OSIRIS, an entirely in-house developed drug discovery informatics system. J Chem Inf Model 2009; 49; 232-46.
17. Satyanarayana D, Revanasiddappa BC, Nemma KV. Synthesis and biological evaluation of some novel pyrazoline derivatives. Indian J Heterocyclic Chem 2013; 22; 353-6.
18. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985; 85: 367-70.
19. Zaho YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G et al. Rate-limited steps of human oral absorption and QSAR studies. Pharm Res 2002; 19: 1446-57.